Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 7/20 | 0.57 |
| ▸ | NOS1 | P29475 | 6/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | NOS3 | P29474 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | GSR | P00390 | 1/20 | 0.52 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.51 |
| ▸ | ARG2 | P78540 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ARG1 | P05089 | 3/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21802128 | 1.00 | NOS2 (0.57) | NOS2NOS1BLMNOS3CYP1A2 | |
| SCHEMBL14031296 | 0.98 | NOS2 (0.56) | NOS2NOS1BLMNOS3CYP1A2 | |
| SCHEMBL14439654 | 0.98 | NOS2 (0.56) | NOS2NOS1BLMNOS3CYP1A2 | |
| SCHEMBL29588594 | 0.98 | NOS2 (0.56) | NOS2NOS1BLMNOS3CYP1A2 | |
| SCHEMBL24767454 | 0.96 | NOS2 (0.57) | NOS2NOS1BLMNOS3CYP1A2 | |
| SCHEMBL16892793 | 0.96 | NOS2 (0.57) | NOS2NOS1BLMNOS3CYP1A2 | |
| SCHEMBL16155902 | 0.96 | NOS2 (0.57) | NOS2NOS1BLMNOS3CYP1A2 | |
| SCHEMBL23586514 | 0.96 | NOS2 (0.57) | NOS2NOS1BLMNOS3CYP1A2 | |
| SCHEMBL16892792 | 0.96 | NOS2 (0.57) | NOS2NOS1BLMNOS3CYP1A2 | |
| Hydrochloric Acid SCHEMBL28356364 | 0.94 | NOS2 (0.56) | NOS2NOS1BLMNOS3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228955-A1 | PLATFORM TECHNOLOGY FOR BISPECIFIC ANTIGENBINDING PROTEINS | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2025-07-17 | — | — | US | claimed |
| WO-2023250380-A2 | PLATFORM TECHNOLOGY FOR BISPECIFIC ANTIGEN-BINDING PROTEINS | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2023-12-28 | — | — | WO | claimed |
| US-12480950-B2 | AKT-specific capture agents, compositions, and methods of using and making | REGENERON PHARMACEUTICALS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250264471-A1 | AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | INDI MOLECULAR, INC. | 2025-08-21 | — | — | US | disclosed |
| US-20250228955-A1 | PLATFORM TECHNOLOGY FOR BISPECIFIC ANTIGENBINDING PROTEINS | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2025-07-17 | — | — | US | disclosed |
| US-20240327850-A1 | METHODS AND COMPOSITIONS FOR CONTROLLING RELEASE FACTOR ACTIVITY AND USES THEREOF | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-10-03 | — | — | US | disclosed |
| US-20240271122-A1 | METHODS FOR CODON OPTIMIZATION AND USES THEREOF | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-08-15 | — | — | US | disclosed |
| US-20240158735-A1 | METHODS AND COMPOSITIONS USING AN ENGINEERED RELEASE FACTOR | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-05-16 | — | — | US | disclosed |
| WO-2024073442-A1 | METHODS FOR ISOLATING, DETECTING, AND QUANTIFYING INTERCELLULAR PROTEINS | FRED HUTCHINSON CANCER CENTER (US) | 2024-04-04 | — | — | WO | disclosed |
| CN-110730787-B | Modified microcystins and arthrosrottoxins | 辛利斯生物制药有限责任公司 | 2023-11-03 | — | — | CN | disclosed |
| WO-2022235825-A1 | METHODS AND COMPOSITIONS FOR CONTROLLING RELEASE FACTOR ACTIVITY AND USES THEREOF | Opentrons LabWorks Inc. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022221576-A1 | METHODS FOR CODON OPTIMIZATION AND USES THEREOF | Opentrons LabWorks Inc. (US) | 2022-10-20 | — | — | WO | disclosed |
| CN-110730787-A | Modified microcystins and nodulotoxins | 赛安诺生物技术有限责任公司 | 2020-01-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12480950-B2 | AKT-specific capture agents, compositions, and methods of using and making | PIK3CA, AKT3, AKT2 | GLA 3305/4885NOS2 3820/4885NOS1 3788/4885 |
| US-20250228955-A1 | PLATFORM TECHNOLOGY FOR BISPECIFIC ANTIGENBINDING PROTEINS | CD2BP2, CD2, DBNL | GLA 3618/4885NOS2 2660/4885NOS1 2697/4885 |
| US-20250264471-A1 | AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING | PIK3CA, AKT3, AKT2 | GLA 3305/4885NOS2 3820/4885NOS1 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.